Drug Trial Radar · NCT05838729
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Apr 3, 2023
Primary completion
Sep 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Coordination Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- University of Illinois Chicago
- First posted
- May 1, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Conditions
- Head Neck Cancer
- Intratumoral Injection
Interventions
RiMO-301Drug
A single dose of RiMO-301 will be administered via an intratumoral injection. PD-1 inhibitor (pembrolizumab or nivolumab) will be administered via a 30-minute intravenous infusion until disease progression or unacceptable toxicity. Patients will receive hypofractionated radiation in 5 fractions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determination of Recommended DoseTime frame: 6 weeks
- Evaluation of Anti-Tumor ResponseTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Illinois at Chicago
Chicago, Illinois · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.